jueves, 22 de mayo de 2014

NHLBI Press Releases: Common treatments for patients with progressive, chronic lung disease found to be ineffective, and more

NHLBI_Standard_Sig_Logo_RGB - New

Press Releases

A drug used to treat patients with mild to moderate lung damage from the disease idiopathic pulmonary fibrosis (IPF) is no better than placebo for preserving lung function, according to a study supported by the National Institutes of Health. The finding is in the final report of a clinical trial called Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis (PANTHER-IPF). It will be published May 23 in the New England Journal of Medicine.
WHAT: Supplementing inhaled corticosteroids (ICS) with vitamin D does not reduce the rate of treatment failure in patients with asthma and vitamin D insufficiency, finds a new National Institutes of Health-funded study. The Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial randomized 408 adults with low vitamin D and mild/moderate asthma to receive the ICS ciclesonide supplemented with either high-dose vitamin D3 or placebo; the participants were then monitored over 28 weeks for the occurrence of worsening asthma.
Related links:
Statin therapy does not prevent exacerbations of chronic obstructive pulmonary disease (COPD) or lower mortality from acute respiratory distress syndrome (ARDS), report two studies that rigorously tested the benefit of the cholesterol-lowering drugs on outcomes in the lung diseases. The findings from the studies funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health were presented at the American Thoracic Society (ATS) annual meeting on May 18, with corresponding online publication in the New England Journal of Medicine.
Related links:
  • Health Topic: ARDS
  • Health Topic: COPD
May is Asthma Awareness Month, and the National Institutes of Health emphasizes the scientific progress being made in asthma research, from basic science, such as how lung cells work, to clinical trials on current and future treatments for the disease. NIH-led research includes studies of environmental factors, how the body’s own defense system plays a role, and the microbiome — all the microbial organisms that live in and on the human body.
Related links:

No hay comentarios:

Publicar un comentario